MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, PASG had -$4,853K decrease in cash & cash equivalents over the period.

Cash Flow Overview

Change in Cash
-$4,853K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Net loss
-32,539 -
Depreciation and amortization
181 370
Sharebased compensation
611 1,781
Amortization of premium and discount on marketable securities, net
0 129
Impairment of long-lived assets
2,637 -
Other non-cash items
0 14
Prepaid expenses and other current assets, and other assets
235 571
Prepaid research and development
33 66
Non-refundable sublicense and transition services payments received
2,500 1,515
Right of use assets and operating lease liabilities
122 215
Accounts payable
66 1,653
Accrued expenses and other current liabilities
-72 -2,634
Net cash provided by (used in) operating activities
-4,853 -20,177
Sales or maturities of marketable securities
0 39,046
Sale of property and equipment and other assets
0 1,170
Net cash provided by (used in) investing activities
0 40,216
Proceeds from the issuance of common stock under employee stock purchase plan
0 14
Net cash provided by (used in) financing activities
0 14
Net increase (decrease) in cash and cash equivalents
-4,853 20,053
Cash and cash equivalents at beginning of period
37,573 -
Cash and cash equivalents at end of period
52,773 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

Passage BIO, Inc. (PASG)

Passage BIO, Inc. (PASG)